Research programme: oral cancer therapeutics - Introgen/Colgate-Palmolive
Latest Information Update: 18 Feb 2010
At a glance
- Originator Introgen Therapeutics
- Developer Colgate-Palmolive; Introgen Therapeutics
- Class
- Mechanism of Action Tumour suppressor gene transcription stimulants; Tumour suppressor protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer